Hi-Tech Diabetic Products To Play Key Role In Firm’s Growth Strategy
This article was originally published in The Tan Sheet
Executive Summary
Hi-Tech Pharmacal plans to build up its Health Care Products Division through a two-pronged approach involving launching new products aimed at diabetics and expanding distribution channels
You may also be interested in...
Hi-Tech Pharmacal Ups R&D Spending At Expense Of Earnings
Hi-Tech Pharmacal nearly doubled its research and development spending in its second fiscal quarter as the firm worked on Rx and OTC generic versions of a number of branded drug products
Hi-Tech Pharmacal
Year-end sales rose to $56.4 mil., up 19% from the prior-year period, the company announces July 13. Net income for the fiscal year ended April 30 increased 15% to $6.6 mil., the Amityville, N.Y.-based company says. Although the Health Care Products division saw a 9% sales decrease, revenue for the DiabetiDerm line increased by 46%, which the firm attributes to strong sales of the line's foot cream containing L-Arginine. The company says it "intends to stay focused on branded products targeting the diabetes market and related areas, including podiatry and dermatology." Hi-Tech Pharmacal identified its increasing interest in products for diabetics last year (1"The Tan Sheet" Sept. 29, 2003, p. 10)...
Abbott’s Ross Division Shows Healthy Growth On Pediatric Nutritional Sales
A double-digit sales increase for pediatric nutritional products leads Abbott Laboratories' Ross consumer healthcare division to its strongest quarter of the year